Cytora Stem

Cytora is a clinical-stage regenerative medicine company developing allogeneic cell therapies derived from human oral mucosa stem cells (hOMSCs) — a unique neural crest-derived population with regenerative, neuroprotective, and immunomodulatory properties. Its lead candidate, hOMSC200, has demonstrated statistically significant efficacy and a strong safety profile in a completed Phase 2a trial for wound management (diabetic foot ulcers). The company is now expanding its platform into neurodegenerative diseases, including Multiple System Atrophy (MSA) and Parkinson’s disease, with additional pipeline programs in spinal cord injury and neuropathic pain. Leveraging Florida’s new SB 1768 legislation, which permits physician-led access to non-FDA-approved stem cell therapies, Cytora is finalizing a partnership with a major U.S.-based CDMO and preparing for early commercialization in 2026 for indications in wound management and neuropathic pain.